The company added that the investigational prophylactic vaccine is currently in a Phase 2b proof of concept study to investigate the safety and efficacy of the vaccine against RSV
in adults aged 65 years and older.
Older adults are among the populations at highest risk of developing RSV
, a highly-contagious, potentially life-threatening respiratory infection that affects more than 64 million people each year worldwide.1
According to the latest report "RSV
Diagnostics Market 2019 Global Analysis Product, Method, End-User and Region with Forecast To 2023, published by Market Research Future, the Global RSV
Diagnostics Market Forecast Covering Growth Inclinations & Development Strategies until 2023
We all are aware of the extra vulnerability to respiratory viruses (RSV
being the most frequent) in premature infants, those with chronic lung disease, or those with congenital heart syndromes; such vulnerable patients are not infrequently seen in routine practice.
causes epidemics in the winter in regions with temperate climates (8,9).
During four RSV
seasons (2013-14 through 2016-17), approximately 3,000-5,000 cases were reported each season in Arizona.
(7) In Saudi Arabia, a study performed during a 3-year period (April 1993-March 1996) on Saudi children showed that 79% of the children admitted to King Khalid University Hospital (KKUH) with an acute respiratory tract infection were diagnosed with RSV
Currently, there is no effective and safe medication or vaccine for RSV
infections, and infection with this virus continues to be a clinical problem worldwide.
Three known types of influenza viruses (A, B, and C) currently circulate in the human population, Types A and B are associated with clinically important respiratory illness.4 Respiratory syncytial virus (RSV
) is best known for its tendency to cause bronchiolitis in infants, but it can infect all age groups causing upper and lower respiratory tract infections ranging in severity from subclinical infections to pneumonia and death.5
Patients with confirmed RSV
bronchiolitis were included in the study.
Participants received oral treatment with 1,000 mg RSV
(RSVhigh), 150 mg RSV
(RSVlow), or placebo daily for 16 weeks.